semaglutide deaths Wegovy reduced Covid in obese patients: study GLP-1 use linked to better

The SURMOUNT-1 trial evaluating tirzepatide demonstrated substantial results, with participants achieving mean weight reductions of approximately 15% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) over 72 weeks

Secondary endpoints at the 12mg dose included: fasting insulin reduction of 41%, triglyceride reduction of ~40%, waist circumference reduction of 18.5 cm, and meaningful improvements in liver fat fraction on MRI in a subset of participants

10.1042/bj2880249 221

However, its modest efficacy and risks for adverse events including bleeding have limited widespread use, Jones said

Liu, Q., Yuan, Y., Zhu, F., Hong, Y